BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37190710)

  • 21. Comparative influence of cribriform growth and percent Gleason 4 in prostatic biopsies with Gleason 3+4 cancer.
    Czaja RC; Tarima S; Wu R; Palagnmonthip W; Iczkowski KA
    Ann Diagn Pathol; 2021 Jun; 52():151725. PubMed ID: 33610958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance.
    Ericson KJ; Wu SS; Lundy SD; Thomas LJ; Klein EA; McKenney JK
    J Urol; 2020 Feb; 203(2):311-319. PubMed ID: 31483693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores.
    Okubo Y; Sato S; Hasegawa C; Koizumi M; Suzuki T; Yamamoto Y; Yoshioka E; Ono K; Washimi K; Yokose T; Kishida T; Miyagi Y
    Hum Pathol; 2023 May; 135():99-107. PubMed ID: 36738975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraductal Carcinoma of the Prostate: To Grade or Not to Grade.
    Surintrspanont J; Zhou M
    Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
    Seyrek N; Hollemans E; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Bangma CH; Rietbergen J; Roobol MJ; Schoots IG; van Leenders GJLH
    Histopathology; 2022 Feb; 80(3):558-565. PubMed ID: 34706119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraductal carcinoma of the prostate.
    Robinson B; Magi-Galluzzi C; Zhou M
    Arch Pathol Lab Med; 2012 Apr; 136(4):418-25. PubMed ID: 22458904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
    Epstein JI; Amin MB; Reuter VE; Humphrey PA
    Am J Surg Pathol; 2017 Apr; 41(4):e1-e7. PubMed ID: 28177964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Grading of prostate cancer: the impact of including intraductal carcinoma on the overall Grade Group assigned in diagnostic biopsies.
    Chen-Maxwell D; Prendeville S
    Histopathology; 2020 Sep; 77(3):503-507. PubMed ID: 32358793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists.
    Gandhi JS; Smith SC; Paner GP; McKenney JK; Sekhri R; Osunkoya AO; Baras AS; DeMarzo AM; Cheville JC; Jimenez RE; Trpkov K; Colecchia M; Ro JY; Montironi R; Menon S; Hes O; Williamson SR; Hirsch MS; Netto GJ; Fine SW; Sirohi D; Kaushal S; Sangoi A; Robinson BD; Kweldam CF; Humphrey PA; Hansel DE; Schultz L; Magi-Galluzzi C; Przybycin CG; Shah RB; Mehra R; Kunju LP; Aron M; Kryvenko ON; Kench JG; Kuroda N; Tavora F; van der Kwast T; Grignon DJ; Epstein JI; Reuter VE; Amin MB
    Am J Surg Pathol; 2020 May; 44(5):673-680. PubMed ID: 31876580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.
    Cohen RJ; Wheeler TM; Bonkhoff H; Rubin MA
    Arch Pathol Lab Med; 2007 Jul; 131(7):1103-9. PubMed ID: 17616999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of the presence of intraductal carcinoma of the prostate and bone metastasis in needle biopsy for prostate carcinoma patients with Grade Group 5.
    Chen X; Yang Y; Wang W; Han B; Qi M; Geng S; Xu J; Zhang Q; Wang X; Chen S; Shi K; Ke X; Zhang J
    Pathol Res Pract; 2020 Jan; 216(1):152693. PubMed ID: 31734052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort.
    Trudel D; Downes MR; Sykes J; Kron KJ; Trachtenberg J; van der Kwast TH
    Eur J Cancer; 2014 Jun; 50(9):1610-6. PubMed ID: 24703897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.
    Guo CC; Epstein JI
    Mod Pathol; 2006 Dec; 19(12):1528-35. PubMed ID: 16980940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraductal carcinoma of the prostate: What we know and what we do not know.
    Chen X; Ding B; Zhang P; Geng S; Xu J; Han B
    Pathol Res Pract; 2018 May; 214(5):612-618. PubMed ID: 29628124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists.
    Varma M; Egevad L; Algaba F; Berney D; Bubendorf L; Camparo P; Comperat E; Erbersdobler A; Griffiths D; Grobholz R; Haitel A; Hulsbergen-van de Kaa C; Langner C; Loftus B; Lopez-Beltran A; Mayer N; Nesi G; Oliveira P; Oxley J; Rioux-Leclercq N; Seitz G; Shanks J; Kristiansen G
    J Clin Pathol; 2016 Oct; 69(10):852-7. PubMed ID: 26926101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Clinical Impact of Comedonecrosis Within Intraductal Carcinoma of the Prostate.
    Wang Y; Teramoto Y; Weisenthal SJ; Goto T; Miyamoto H
    Arch Pathol Lab Med; 2023 Jan; 147(1):94-99. PubMed ID: 35472669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
    Seyrek N; Hollemans E; Andrinopoulou ER; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Remmers S; Schoots IG; van Leenders GJLH
    Virchows Arch; 2022 Jun; 480(6):1149-1157. PubMed ID: 35157140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
    Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presence of corpora amylacea among prostate cancer cells: an unrecognised feature of intraductal carcinoma of the prostate.
    Sugie M; Takahara T; Ohashi A; Sassa N; Tsuzuki T
    Pathology; 2021 Aug; 53(5):574-578. PubMed ID: 34154844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.
    Kweldam CF; Kümmerlin IP; Nieboer D; Verhoef EI; Steyerberg EW; van der Kwast TH; Roobol MJ; van Leenders GJ
    Mod Pathol; 2016 Jun; 29(6):630-6. PubMed ID: 26939875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.